| Description | Description
Ongoing research and exciting new discoveries in treating COVID-19 are shaping the way we work with viruses and viral infections. David Veesler (from the Howard Hughes Medical Institute and the University of Washington School of Medicine) and his team of researchers have worked to target antibodies on the spike protein and uncovered new discoveries to help scientists design vaccines and antibody treatments that would work not just against the Omicron variant but against any mutations that could appear in the future. Join us for an afternoon with Professor David Veesler as we discuss this discovery and ongoing research in the treatment of COVID-19.
About Our Speakers
David Veesler, PhD is a professer and researcher at Veesler Labs. Our research program aims to elucidate how pathogens gain access to host cells and how the immune system responds to infection with a special emphasis on emerging and re-emerging enveloped viruses. We are at the forefront of the viral fusion glycoprotein field and develop innovative and integrative methods to understand glycoprotein-mediated attachment to host receptors and membrane fusion, cross-species transmission of viruses as well as the humoral immune response elicited by infection and vaccination in humans and animals.
Our work combines both fundamental research and translational studies and spans structural biology, virology, microbiology, immunology, biochemistry, biophysics and genomics. We designed, discovered, characterized and/or developed several molecules currently used in the clinic, evaluated in clinical trials or about to enter clinical trials, including a COVID-19 monoclonal antibody therapy, vaccines against SARS-CoV-2 (protein subunit and nucleic acid based), influenza virus and respiratory syncytial virus as well as synthetic miniprotein viral inhibitors.
Thanks to our sponsors at BECU and AT&T |
|---|